TY - JOUR
T1 - Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
AU - Santos da Silva, Eveline
AU - Servais, Jean-Yves
AU - Kohnen, Michel
AU - Arendt, Vic
AU - Staub, Therese
AU - The CoVaLux Consortium, Report Consortium
AU - The CoVaLux Consortium, Report Consortium
AU - Krüger, Rejko
AU - Fagherazzi, Guy
AU - Wilmes, Paul
AU - Hübschen, Judith M
AU - Ollert, Markus
AU - Perez-Bercoff, Danielle
AU - Seguin-Devaux, Carole
N1 - Funding
This research was funded by the Luxembourg National Research Fund (FNR) (NEUTRACOV, grant number 14718697), the Rotary Club Luxembourg, EATRIS TRANSVAC-2, and the Ministère de l’Education et de la Recherche du Luxembourg. The CON-VINCE study was supported by the Fonds National de la Recherche (FNR: 14716281/CON-VINCE/Kruger), and the André Losch Foundation (Luxembourg). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101016167. The Predi-COVID study was supported by the Luxembourg National Research Fund (FNR) (Predi-COVID, grant number 14716273), the André Losch Foundation, and the European Regional Development Fund (FEDER, convention 2018-04-026-21). The work was further supported by the Luxembourg Government through the CoVaLux programme. The funders had no role in the design and conduct of the study, nor in the decision to prepare and submit the manuscript for publication
PY - 2023/10/6
Y1 - 2023/10/6
N2 - SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman’s r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the “Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit” and the “Genscript cPass, kit” revealed an overall good correlation ranging from 0.8673 to −0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (n = 100) and an Omicron-breakthrough infection cohort (n = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs.
AB - SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman’s r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the “Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit” and the “Genscript cPass, kit” revealed an overall good correlation ranging from 0.8673 to −0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (n = 100) and an Omicron-breakthrough infection cohort (n = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs.
KW - immunity
KW - neutralizing antibodies
KW - SARS-CoV-2
KW - vaccines
KW - viral neutralization assay
UR - http://www.scopus.com/inward/record.url?scp=85174674155&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/37834413
U2 - 10.3390/ijms241914965
DO - 10.3390/ijms241914965
M3 - Article
C2 - 37834413
SN - 1661-6596
VL - 24
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 19
M1 - 14965
ER -